Stock 301281 SHANDONG KEYUAN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shandong Keyuan Pharmaceutical Co., Ltd.

Equities

301281

CNE1000061V8

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-06-13 pm EDT 		5-day change 1st Jan Change
23.68 CNY -0.29% Intraday chart for Shandong Keyuan Pharmaceutical Co., Ltd. +2.82% -30.43%
Apr. 21 Shandong Keyuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 04 Certain A Shares of Shandong Keyuan Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 4-APR-2024. CI

Valuation

Fiscal Period: December 2023
Capitalization 1 3,686
Enterprise Value (EV) 1 3,000
P/E ratio 44.8 x
Yield 0.88%
Capitalization / Revenue 8.24 x
EV / Revenue 6.7 x
EV / EBITDA 28.4 x
EV / FCF -76.2 x
FCF Yield -1.31%
Price to Book 2.77 x
Nbr of stocks (in thousands) 108,290
Reference price 2 34.04
Announcement Date 3/28/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 245.5 311.5 367.1 420.9 442.9 447.6
EBITDA 1 62.29 92.24 99.63 109.5 120.8 105.6
EBIT 1 45.81 68.46 75.85 82.64 88.91 58.25
Operating Margin 18.66% 21.98% 20.66% 19.63% 20.08% 13.01%
Earnings before Tax (EBT) 1 45.18 59.16 81.08 89.92 98.3 79.74
Net income 1 40.55 50.42 68.65 78.17 91.28 77.04
Net margin 16.52% 16.19% 18.7% 18.57% 20.61% 17.21%
EPS 2 0.7000 0.8700 0.8429 0.9643 1.121 0.7600
Free Cash Flow 1 -10.92 -3.869 74.71 81.63 60.98 -39.35
FCF margin -4.45% -1.24% 20.35% 19.4% 13.77% -8.79%
FCF Conversion (EBITDA) - - 74.99% 74.55% 50.48% -
FCF Conversion (Net income) - - 108.83% 104.43% 66.81% -
Dividend per Share - - - - 0.2857 0.3000
Announcement Date 4/26/19 4/27/20 6/23/21 3/16/23 4/25/23 3/28/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 55 - - - -
Net Cash position 1 11.8 - 37.4 66 149 686
Leverage (Debt/EBITDA) - 0.5967 x - - - -
Free Cash Flow 1 -10.9 -3.87 74.7 81.6 61 -39.4
ROE (net income / shareholders' equity) 15.4% 16.5% 22.3% 20.2% 19.2% 8.33%
ROA (Net income/ Total Assets) 8.45% 9.13% 9.89% 10.1% 9.17% 3.43%
Assets 1 479.9 552 694.3 770.4 994.9 2,245
Book Value Per Share 2 4.640 5.260 4.210 5.310 6.400 12.30
Cash Flow per Share 2 0.4000 0.5900 0.4600 0.8100 1.830 3.000
Capex 1 27.9 18.2 7.13 20.2 31.1 70.1
Capex / Sales 11.35% 5.86% 1.94% 4.8% 7.02% 15.67%
Announcement Date 4/26/19 4/27/20 6/23/21 3/16/23 4/25/23 3/28/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
SHANDONG KEYUAN PHARMACEUTICAL CO., LTD. Stock Shandong Keyuan Pharmaceutical Co., Ltd.
-30.43% 353M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.21% 791B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.21% 630B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.80% 328B
ABBVIE INC. Stock AbbVie Inc.
+9.48% 298B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.36% 246B
ROCHE HOLDING AG Stock Roche Holding AG
+0.37% 225B
NOVARTIS AG Stock Novartis AG
+9.89% 218B
AMGEN INC. Stock Amgen Inc.
+3.24% 160B
PFIZER, INC. Stock Pfizer, Inc.
-5.40% 156B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 301281 Stock
  4. Financials Shandong Keyuan Pharmaceutical Co., Ltd.